Anticoagulant use in nonvalvular atrial fibrillation

References

• Ezekowitz M, Cohen I, Gornick C, et al. Atrial fibrillation. In: Daniel WG, Kronzon I, Mügge A, eds. Cardiogenic embolism. Baltimore: Williams & Wilkins, 1996:27–44
   Google Scholar
• Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989; 1(8631): 175–9
   PubMed Web of Science ®Google Scholar
• Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322(12):863–8
   Google Scholar
• Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84(2):527–39
   PubMed Web of Science ®Google Scholar
• The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323(22): 1505–11
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18(2):349–55
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327(20): 1406–12
   PubMed Web of Science ®Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154(13):1449–57
   PubMed Web of Science ®Google Scholar
• The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157(11):1237–40
   Google Scholar
• EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342(8882):1255–62
   PubMed Web of Science ®Google Scholar
• Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343(8899):687–91
   PubMed Web of Science ®Google Scholar
• The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279(16):1273–7
   PubMed Web of Science ®Google Scholar
• The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156(4):409–16
   Google Scholar
• Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124(11):970–9
   Google Scholar
• Adjusted-dose warfarin versus low- intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348(9028):633–8
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan AM, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335(8):540–6
   PubMed Web of Science ®Google Scholar
• Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120(11): 897–902
   PubMed Web of Science ®Google Scholar
• Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333(1):5–10
   PubMedGoogle Scholar
• van Gijn J. Low doses of aspirin in stroke prevention. Lancet 1999; 353(9171): 2172–3
   Google Scholar
• Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1 066 patients from 3 clinical trials. Arch Intern Med 1998; 158(12):1316–20
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128(8):639–47
   PubMed Web of Science ®Google Scholar
• Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med 1996; 156(19):2221–4
   Google Scholar
• Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989; 117(4):976–7
   Google Scholar
• Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA 1962; 182:548–55
   PubMed Web of Science ®Google Scholar
• Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23(2):208–16
   PubMed Web of Science ®Google Scholar
• O'Neill PG, Puelo P, Bolli R, et al. Return of atrial mechanical function following electrical cardioversion of atrial dysrhythmias. Am Heart J 1990; 120(2):353–9
   Google Scholar
• The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management—the AFFIRM study design. Am J Cardiol 1997; 79(9):1198–1202
   Google Scholar
• Goldman M. The management of chronic atrial fibrillation: indications and method of conversion to sinus rhythm. Prog Cardiovasc Dis 1959; 2:465–9
   Google Scholar
• Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126(8):615–20
   PubMed Web of Science ®Google Scholar
• Manning WJ, Silverman DI, Keighly CS, et al. Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study. J Am Coll Cardiol 1995; 25(6):1354–61
   Google Scholar
• Salka S, Saeian K, Sagar KB. Cerebral thromboembolization after cardioversion of atrial fibrillation in patients without transesophageal echocardiographic findings of left atrial thrombus. Am Heart J 1993; 126(3 pt 1):722–4 32. Klein AL, Grimm RA, Black LW, et al. Cardioversion guided by transesophageal echocardiography: The ACUTE Pilot Study. A randomized, controlled trial. Ann Intern Med 1997; 126(3):200–9
   Google Scholar
• Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114(5 Supp1);579–89S
   Google Scholar
• Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28(5): 1015–21
   Google Scholar